Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Cantargia reports first patient treated in CAPAFOUR study


96413 Helge Larsen/PI-redaktør 26/8 2021 13:16
1
Oversigt

00 PM CEST / 26-Aug-2021 / Cantargia AB (STO:CANTA)

Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer

Cantargia AB today announced that the first patient has received treatment with nadunolimab (CAN04) and FOLFIRINOX in the phase Ib study, CAPAFOUR, investigating treatment of patients with metastatic pancreatic cancer (PDAC). The study will include approximately 30 patients at multiple sites in France and Spain.

The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is Cantargia's most advanced program. The first patient has now been dosed in the phase Ib study CAPAFOUR, investigating CAN04 in combination with one of the two most commonly used first line chemotherapy regimens in metastatic PDAC, FOLFIRINOX. CAPAFOUR will be conducted at three sites in France and five sites in Spain. Approximately 30 patients are planned to be enrolled and recruitment is estimated to take 18-24 months.

CAN04 is currently evaluated in several clinical trials, including a phase I/IIa study, CANFOUR, which is examining first line combination with gemcitabine and nab-paclitaxel in patients with advanced PDAC, and gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) (https://clinicaltrials.gov/ct2/show/NCT03267316). Additional clinical studies investigating CAN04 combination with chemotherapy for treatment of various forms of cancer will initiate during 2021. Further, CAN04 is evaluated in combination with a checkpoint inhibitor, pembrolizumab, in four different solid tumor indications in the phase Ib study CIRIFOUR (https://clinicaltrials.gov/ct2/show/NCT04452214).

The primary objective of CAPAFOUR is to assess the safety and tolerability of CAN04 combined with FOLFIRINOX. The patients will receive CAN04 and FOLFIRINOX for up to 12 cycles. The initial part of the study, a dose escalation phase with increasing doses of CAN04 in combination with FOLFIRINOX, will include up to 15 patients. The second part, an expansion phase, will explore the highest safe dose of CAN04 in up to 15 additional patients. Secondary endpoints include effects on serum biomarkers, such as IL-6 and CRP, biopsy analysis and antitumor efficacy. Additional trial details can be found on https://clinicaltrials.gov/ct2/show/NCT04990037.

"As Cantargia's vision is to provide cancer patients with novel treatments, the start of this trial is a moment of pride. Based on the synergies observed between CAN04 and platinum-based chemotherapy, we have high expectations on the outcome of this study.", said Göran Forsberg, CEO of Cantargia.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com


Obs: Cantargia har digital IR aftale med ProInvestor.com



TRÅDOVERSIGT